Wellington Management Group’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-411,523
| Closed | -$1.25M | – | 2077 |
|
|
2024
Q4 | $1.25M | Sell |
411,523
-34,504
| -8% | -$150K | ﹤0.01% | 1678 |
|
|
2024
Q3 | $2.31M | Buy |
+446,027
| New | +$2.22M | ﹤0.01% | 1512 |
|
|
2024
Q2 | – | Sell |
-76,413
| Closed | -$376K | – | 1991 |
|
|
2024
Q1 | $376K | Sell |
76,413
-373,272
| -83% | -$2.21M | ﹤0.01% | 1833 |
|
|
2023
Q4 | $3.95M | Sell |
449,685
-632,735
| -58% | -$5.18M | ﹤0.01% | 1360 |
|
|
2023
Q3 | $12.4M | Buy |
1,082,420
+37,131
| +4% | +$714K | ﹤0.01% | 1049 |
|
|
2023
Q2 | $26.5M | Sell |
1,045,289
-95,871
| -8% | -$2.99M | 0.01% | 870 |
|
|
2023
Q1 | $36.8M | Sell |
1,141,160
-153,515
| -12% | -$4.79M | 0.01% | 774 |
|
|
2022
Q4 | $23.9M | Buy |
1,294,675
+961,998
| +289% | +$22M | ﹤0.01% | 874 |
|
|
2022
Q3 | $8.98M | Sell |
332,677
-11,790
| -3% | -$239K | ﹤0.01% | 1129 |
|
|
2022
Q2 | $4.76M | Sell |
344,467
-321
| -0.1% | -$4.94K | ﹤0.01% | 1339 |
|
|
2022
Q1 | $6.72M | Sell |
344,788
-694,124
| -67% | -$10.5M | ﹤0.01% | 1301 |
|
|
2021
Q4 | $17M | Sell |
1,038,912
-178,181
| -15% | -$2.97M | ﹤0.01% | 1117 |
|
|
2021
Q3 | $33.9M | Sell |
1,217,093
-1,553,147
| -56% | -$44.3M | 0.01% | 932 |
|
|
2021
Q2 | $82.1M | Sell |
2,770,240
-65,451
| -2% | -$1.89M | 0.01% | 689 |
|
|
2021
Q1 | $79.3M | Sell |
2,835,691
-432,426
| -13% | -$12M | 0.01% | 674 |
|
|
2020
Q4 | $92.6M | Sell |
3,268,117
-294,474
| -8% | -$7.63M | 0.02% | 606 |
|
|
2020
Q3 | $89.6M | Sell |
3,562,591
-194,207
| -5% | -$5.09M | 0.02% | 547 |
|
|
2020
Q2 | $91.7M | Sell |
3,756,798
-1,869,621
| -33% | -$36.9M | 0.02% | 547 |
|
|
2020
Q1 | $83.3M | Sell |
5,626,419
-161,626
| -3% | -$3.34M | 0.02% | 504 |
|
|
2019
Q4 | $93.9M | Buy |
5,788,045
+376,573
| +7% | +$5.84M | 0.02% | 589 |
|
|
2019
Q3 | $70.3M | Sell |
5,411,472
-291,995
| -5% | -$3.57M | 0.02% | 625 |
|
|
2019
Q2 | $74M | Sell |
5,703,467
-40,667
| -0.7% | -$513K | 0.02% | 646 |
|
|
2019
Q1 | $90.5M | Buy |
5,744,134
+1,432,790
| +33% | +$24.8M | 0.02% | 572 |
|
|
2018
Q4 | $86.8M | Buy |
4,311,344
+296,001
| +7% | +$6.52M | 0.02% | 550 |
|
|
2018
Q3 | $99.8M | Buy |
4,015,343
+232,756
| +6% | +$6.33M | 0.02% | 587 |
|
|
2018
Q2 | $104M | Sell |
3,782,587
-31,447
| -0.8% | -$945K | 0.02% | 570 |
|
|
2018
Q1 | $117M | Buy |
3,814,034
+240,884
| +7% | +$7.75M | 0.03% | 529 |
|
|
2017
Q4 | $128M | Buy |
3,573,150
+1,231,640
| +53% | +$35.4M | 0.03% | 483 |
|
|
2017
Q3 | $64.5M | Buy |
2,341,510
+401,698
| +21% | +$9.74M | 0.01% | 676 |
|
|
2017
Q2 | $51.2M | Sell |
1,939,812
-151,995
| -7% | -$3.39M | 0.01% | 725 |
|
|
2017
Q1 | $43.5M | Sell |
2,091,807
-57,871
| -3% | -$1.19M | 0.01% | 775 |
|
|
2016
Q4 | $44.5M | Sell |
2,149,678
-263,662
| -11% | -$4.42M | 0.01% | 749 |
|
|
2016
Q3 | $39.1M | Buy |
2,413,340
+74,792
| +3% | +$1.09M | 0.01% | 767 |
|
|
2016
Q2 | $31.8M | Buy |
2,338,548
+687,122
| +42% | +$12.1M | 0.01% | 799 |
|
|
2016
Q1 | $28.8M | Buy |
1,651,426
+1,130,248
| +217% | +$23M | 0.01% | 817 |
|
|
2015
Q4 | $17.8M | Buy |
521,178
+431,936
| +484% | +$15M | ﹤0.01% | 995 |
|
|
2015
Q3 | $2.66M | Sell |
89,242
-19,380
| -18% | -$589K | ﹤0.01% | 1542 |
|
|
2015
Q2 | $3.47M | Buy |
108,622
+860
| +0.8% | +$22.1K | ﹤0.01% | 1514 |
|
|
2015
Q1 | $2.23M | Sell |
107,762
-52,450
| -33% | -$906K | ﹤0.01% | 1662 |
|
|
2014
Q4 | $2.71M | Buy |
+160,212
| New | +$2.8M | ﹤0.01% | 1608 |
|
Other funds holding RVNC
Wellington Management Group's RVNC Position: Q1 2025 in Review
Wellington Management Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 411,523 shares — an estimated $1.25M sold.
Wellington Management Group first reported a position in RVNC in Q4 2014 and held it in 40 quarters. The position peaked at $128M in Q4 2017. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Wellington Management Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Wellington Management Group sold 411,523 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1.25M.
- Wellington Management Group first reported a position in Revance Therapeutics, Inc. in Q4 2014 and held it in 40 quarters.
- Wellington Management Group's Revance Therapeutics, Inc. position peaked at $128M in Q4 2017.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Wellington Management Group's 13F filing for Q1 2025, filed 13 May 2025.